These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 21788131)
1. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Si L; Kong Y; Xu X; Flaherty KT; Sheng X; Cui C; Chi Z; Li S; Mao L; Guo J Eur J Cancer; 2012 Jan; 48(1):94-100. PubMed ID: 21788131 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048 [TBL] [Abstract][Full Text] [Related]
3. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia. Bezić J; Tomić I; Pavić M Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192 [TBL] [Abstract][Full Text] [Related]
4. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705 [TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205 [TBL] [Abstract][Full Text] [Related]
6. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Saldanha G; Potter L; Daforno P; Pringle JH Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595 [TBL] [Abstract][Full Text] [Related]
8. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis. Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873 [TBL] [Abstract][Full Text] [Related]
9. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma. Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604 [TBL] [Abstract][Full Text] [Related]
10. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166 [TBL] [Abstract][Full Text] [Related]
11. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K; JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664 [TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084 [TBL] [Abstract][Full Text] [Related]
13. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447 [TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669 [TBL] [Abstract][Full Text] [Related]
15. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population. Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409 [TBL] [Abstract][Full Text] [Related]
16. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY; J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and clinical outcomes associated with TP53 and BRAF Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979 [TBL] [Abstract][Full Text] [Related]
18. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Jakob JA; Bassett RL; Ng CS; Curry JL; Joseph RW; Alvarado GC; Rohlfs ML; Richard J; Gershenwald JE; Kim KB; Lazar AJ; Hwu P; Davies MA Cancer; 2012 Aug; 118(16):4014-23. PubMed ID: 22180178 [TBL] [Abstract][Full Text] [Related]
19. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Lee JH; Choi JW; Kim YS Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657 [TBL] [Abstract][Full Text] [Related]
20. BRAF and NRAS mutations in melanoma and melanocytic nevi. Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]